1. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes
- Author
-
Takashi Matsui, Hiroko Aoyagi, Briana K. Shimada, Kate M. Horiuchi, Motoi Kobayashi, Hiroaki Kitaoka, Yuichi Baba, Tomohiro Suhara, Jonathan D. Woo, Jason K. Higa, and Karra S. Marh
- Subjects
Male ,0301 basic medicine ,Programmed cell death ,Cell Survival ,Physiology ,Iron ,Mice, Transgenic ,Myocardial Reperfusion Injury ,Apoptosis ,Phenylenediamines ,Biology ,Ferric Compounds ,Piperazines ,03 medical and health sciences ,Physiology (medical) ,Animals ,Humans ,Myocytes, Cardiac ,Mechanistic target of rapamycin ,Cells, Cultured ,PI3K/AKT/mTOR pathway ,Sirolimus ,Cyclohexylamines ,Cell Death ,TOR Serine-Threonine Kinases ,Ferroptosis ,Cell biology ,Mice, Inbred C57BL ,Death ,030104 developmental biology ,Biochemistry ,biology.protein ,Reactive Oxygen Species ,Cardiology and Cardiovascular Medicine ,Carbolines ,Signal Transduction ,Research Article - Abstract
Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2′,7′-Dichlorodihydrofluorescein diacetate measurement of reactive oxygen species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and ferroptosis. Listen to this article's corresponding podcast at http://ajpheart.podbean.com/e/mtor-prevents-ferroptosis-in-cardiomyocytes/.
- Published
- 2018